IMMXImmix Biopharma, Inc.
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$30M
- 31% YoY
- Market cap
- $549M
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- 2.7
- mentions per 10K words
Takeover score 1 of 13
Fixable underperformance 0 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo—Median CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCNo—Over 10% of revenue
- Payouts exceed cash flowNo-0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo—Over 40% of assets
- Shareholder dissentNo96% lowest supportAny vote under 80% support
Buyer economics 1 of 4
- Low revenue per employeeNo—Bottom quartile of its SIC industry
- Quiet on AINo2.7 per 10K words · 66th pctBottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedYes$549M market capMarket cap $500M–$5B
Catalysts 0 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo$10K netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$1M | −$8M | −$16M | −$23M | −$30M | 32% |
| Net income | −$24M | −$8M | −$15M | −$22M | −$29M | 36% |
| Operating cash flow | −$2M | −$7M | −$11M | −$15M | −$24M | 64% |
| Capex | $802 | — | $52K | $1M | $733K | 38% |
| Stock-based comp | $219K | $624K | $3M | $3M | $2M | 19% |
| Buybacks | — | $100K | — | — | — |
Deal filings
None.
13D filers
| Filed | Filer | Form | Stake | Intent |
|---|---|---|---|---|
| Aug 30, 2023 | GKCC, LLC | SC 13D | 20.0% | Active |
Insider trading
- Open-market buys, 12 mo
- $10K · 2
- Open-market sells, 12 mo
- $0 · 0
- Net
- $10K
Pay vs performance
No pay-versus-performance disclosure yet.